Frontiers in Cell and Developmental Biology (Dec 2021)
Targeted Methylation of the LncRNA NEAT1 Suppresses Malignancy of Renal Cell Carcinoma
- Jieqing Chen,
- Jieqing Chen,
- Jieqing Chen,
- Jieqing Chen,
- Xinhui Liao,
- Xinhui Liao,
- Xinhui Liao,
- Xinhui Liao,
- Jianli Cheng,
- Jianli Cheng,
- Jianli Cheng,
- Ganglin Su,
- Ganglin Su,
- Ganglin Su,
- Fen Yuan,
- Fen Yuan,
- Fen Yuan,
- Zhongfu Zhang,
- Zhongfu Zhang,
- Zhongfu Zhang,
- Jianting Wu,
- Jianting Wu,
- Jianting Wu,
- Hongbing Mei,
- Hongbing Mei,
- Hongbing Mei,
- Wanlong Tan
Affiliations
- Jieqing Chen
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Jieqing Chen
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jieqing Chen
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jieqing Chen
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Xinhui Liao
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Xinhui Liao
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Xinhui Liao
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Xinhui Liao
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jianli Cheng
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jianli Cheng
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jianli Cheng
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Ganglin Su
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Ganglin Su
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Ganglin Su
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Fen Yuan
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Fen Yuan
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Fen Yuan
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Zhongfu Zhang
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Zhongfu Zhang
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Zhongfu Zhang
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jianting Wu
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jianting Wu
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Jianting Wu
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Hongbing Mei
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Hongbing Mei
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Hongbing Mei
- Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Wanlong Tan
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- DOI
- https://doi.org/10.3389/fcell.2021.777349
- Journal volume & issue
-
Vol. 9
Abstract
Long-chain non-coding RNA (LncRNA) has been found to play an important role in the regulation of the occurrence and progression of renal cell carcinoma (RCC). In this study, we demonstrated that LncRNA NEAT1 expression and m6A methylation level was decreased in RCC tissues. Further, the downregulated expression level of LncRNA NEAT1 was associated with poor prognosis for RCC patients. Then we used CRIPSR/dCas13b-METTL3 to methylate LncRNA NEAT1 in RCC cells. The results showed that the expression level of LncRNA NEAT1 was upregulated after methylated by dCas13b-METTL3 in RCC cells. And the proliferation and migration ability of RCC cells was decreased after methylated LncRNA NEAT1. Finally, we examined the effect of LncRNA NEAT1 hypermethylation on the transcriptome. We found differentially expressed genes in RCC cells were associated with “cGMP-PKG signaling pathway”, “Cell adhesion molecules” and “Pathways in cancer”. In conclusion, CRISPR/Cas13b-METTL3 targeting LncRNA NEAT1 m6A methylation activates LncRNA NEAT1 expression and provides a new target for treatment of RCC.
Keywords
